Showing 6261-6270 of 10503 results for "".
- Arcutis Completes Enrollment in Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-phase-3-trial-of-topical-roflumilast-foam-in-scalp-and-body-psoriasis/2461153/Enrollment in Arcutis’ ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis is complete, the company reported. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (
- Aveeno Opens Applications for 2022 Skin Health Startup Accelerator Pitch Competitionhttps://practicaldermatology.com/news/aveeno-opens-applications-for-2022-skin-health-startup-accelerator-pitch-competition/2461150/The Aveeno brand has announced its second year of the Aveeno Skin Health Start
- Scientists Discover Gene Mutation That Signals Aggressive Melanomahttps://practicaldermatology.com/news/scientists-discover-gene-mutation-that-signals-aggressive-melanoma/2461149/Patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports. &l
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Third Annual San Diego Dermatology Symposium (SDDS) Takes Place in Personhttps://practicaldermatology.com/news/third-annual-san-diego-dermatology-symposium-sdds-takes-place-in-person/2461146/By Caroline Tan, MD, UCLA Dermatology Resident, PGY3 Held for the first time in-person at the Hilton San Diego Bayfront, the Third Annual San Diego Dermatology Symposium (SDDS, March 11-13,
- Lilly's Olumiant Associated with Significant Hair Growth in Patients with Severe Alopecia Areatahttps://practicaldermatology.com/news/lillys-olumiant-associated-with-significant-hair-growth-in-patients-with-severe-alopecia-areata/2461144/Olumiant® (baricitinib) from Eli Lilly and company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75% of those who responded to Olumiant 4mg achieving 90% scalp coverage. The 52-week pooled findings were presented at the
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new